Mosby Periodicals Home Visit
ASCPT 		Search User
Pref		 Help
CPT Home Current
Issue 		All
Issues 		Order About this
Journal 		<<
Issue 		>>
Issue

March 2003 • Volume 73 • Number 3


Pharmacokinetics and Drug Disposition
Duloxetine is both an inhibitor and a substrate of cytochrome P4502D6 in healthy volunteers

Michael H. Skinner, MD, PharmD [MEDLINE LOOKUP]
Han-Yi Kuan, PhD [MEDLINE LOOKUP]
Alan Pan, MB, BCh, BAO [MEDLINE LOOKUP]
Korbtham Sathirakul, PhD [MEDLINE LOOKUP]
Mary Pat Knadler, PhD [MEDLINE LOOKUP]
Celedon R. Gonzales, MS [MEDLINE LOOKUP]
Kwee Poo Yeo, PhD [MEDLINE LOOKUP]
Shobha Reddy, BS [MEDLINE LOOKUP]
Maggie Lim, RPh [MEDLINE LOOKUP]
Mosun Ayan-Oshodi, MS [MEDLINE LOOKUP]
Stephen D. Wise, FRCP [MEDLINE LOOKUP]
Indianapolis, Ind, and Singapore
• Previous article in Issue
• Next article in Issue
• View full-text version
• View print version (PDF)
• Drug links from Mosby's DrugConsult
• Genetic information from OMIM
• Citation of this Article
   • View on PubMed
   • Download in citation manager format
   • Download in Medlars format
• Related articles in PubMed

   Abstract  TOP 

Background and Objectives: Duloxetine, a potent dual reuptake inhibitor of serotonin and norepinephrine currently undergoing clinical investigation for treatment of depression and stress urinary incontinence, has the potential to act as both a substrate and an inhibitor of cytochrome P4502D6 (CYP2D6). Our objectives were to determine the effect of duloxetine on the pharmacokinetics of desipramine, a tricyclic antidepressant metabolized by CYP2D6 (study 1), and the effect of paroxetine, a potent CYP2D6 inhibitor, on duloxetine pharmacokinetics (study 2).
Methods: Subjects were healthy men and women between 21 and 63 years old. All subjects were genotypically CYP2D6 extensive metabolizers. In study 1, 50 mg of desipramine was administered as a single dose alone and in the presence of steady-state duloxetine 60 mg twice daily. In study 2, steady-state pharmacokinetics of duloxetine 40 mg once daily were determined in the presence and absence of steady-state paroxetine 20 mg once daily.
Results: Duloxetine increased the maximum plasma concentration of desipramine 1.7-fold and the area under the concentration-time curve 2.9-fold. Paroxetine increased the maximum plasma concentration of duloxetine and the area under the concentration-time curve at steady state 1.6-fold. Reports of adverse events were similar whether duloxetine was administered alone or in combination with desipramine or paroxetine.
Conclusion: Duloxetine 60 mg twice daily is a moderately potent CYP2D6 inhibitor, intermediate between paroxetine and sertraline. The potent CYP2D6 inhibitor paroxetine has a moderate effect on duloxetine concentrations. The results of these 2 studies suggest that caution should be used when CYP2D6 substrates and inhibitors are coadministered with duloxetine. (Clin Pharmacol Ther 2003;73:170-7.)

   Publishing and Reprint Information  TOP